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 Abstract: Multiple sclerosis is a common chronic, disabling autoimmune neurological disease affecting 
mainly young adults. In its pathomechanism, neurodegenerative and acute inflammatory characteristics 
are both involved. Disease-modifying therapies aim to reduce relapse-rate and slow down the deteriora-
tion in neurological functions. The currently available therapies fail to exert neuroprotective effects and 
most of them are associated with potentially toxic side-effects, therefore, ongoing research aims to de-
velop novel drug candidates to cover these therapeutic gaps. The kynurenine pathway has been impli-
cated in both the physiological processes of the central nervous system and in the pathomechanism of 
several neurological disorders as well. Alterations of the kynurenine pathway metabolites have been de-
tected in multiple sclerosis and a number of potential therapeutic targets related to this metabolic route 
have been already identified. Laquinimod is a quinoline carboxamide showing structural similarities 
with kynurenic acid, which proved to have beneficial effects on reduction of brain atrophy and disabil-
ity progression. The kynurenine pathway is therefore a promising target for the development of future 
drugs for the treatment of autoimmune diseases such as multiple sclerosis. 
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INTRODUCTION 
Multiple sclerosis (MS) is a chronic, immune-mediated 
disease of the central nervous system (CNS) causing demye-
lination and axonal damage. It is the second most common 
cause of neurological disability in young adults [1]. The ex-
act pathomechanism of MS is unknown, but both genetic and 
environmental factors are believed to contribute as trigger 
factors to the development of an autoimmune process. MS is 
not an inheritable disease, but several gene loci have been 
identified as risk factors, among them the importance of the 
major histocompatibility complex (MHC) HLA DR15/DQ6 
allele is outstanding [2]. Ebstein-Barr virus infection, ciga-
rette smoking and vitamin D deficiency belong to environ-
mental factors which have been linked to an increased risk of 
MS [2]. The diagnosis of MS is mainly clinical, based on the 
revised version of the McDonald criteria, the main concept 
of which is the verification of symptom dissemination in 
time and space [3]. The most prevalent form is relapsing-
remitting MS (RRMS), in which recurring episodes of neu-
rological symptoms occur. RRMS can later transform into a 
secondary progressive form, when a slow but continuous 
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progression of disability is present without relapses. Approx-
imately 10% of the cases have primary progressive MS [4]. 
For the time being, disease modifying therapy is only availa-
ble to the relapsing-remitting form of the disease. The cur-
rently available treatments for MS are all anti-inflammatory 
which are able to reduce the duration and number of relaps-
es. However, no proved neuroprotective molecules are avail-
able to facilitate remyelination. First line therapies include 
different forms of beta-interferon and glatiramer acetate, 
while intravenous second-line therapies include natalizumab, 
alemtuzumab and mitoxantrone [2]. Until 2010, only paren-
terally administered medications were given to patients. 
Since then, three oral medications, namely fingolimod, teri-
flunamide and dimethyl-fumarate have been approved for the 
treatment of RRMS. All these drug were shown to have po-
tentially toxic side effects, for example cardiotoxicity of mi-
toxantrone, hepatotoxicity of natalizumab and teriflunomide, 
teratogenicity of teriflunomide or the development of pro-
gressive multifocal leukoencephalopathy (PML) in the case 
of natalizumab, fingolimod or dimethyl-fumarate [2, 5]. Be-
cause of the less favourable safety profile, these medications 
remain second line treatments, and a therapeutic challenge is 
to carefully choose the appropriate patients. Novel drugs are 
therefore needed with a more favorable safety profile, and 
also for the treatment of progressive cases of MS. Several 
other oral drugs are currently under clinical trials and are 
expected to add to the armamentarium of MS treatment soon.  
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The kynurenine pathway (KP) is the main metabolic route 
of the essential amino acid tryptophan (Trp). In this cascade of 
enzymatic steps, several neuroactive molecules are produced 
including both neurotoxic and neuroprotective ones. The KP 
and its metabolites have been implicated not only in the phys-
iological functioning of the central nervous system (CNS) but 
also in the pathomechanism of several neurological disorders 
and in the immunoregulation as well [6-9]. The enzyme in-
doleamine-2,3-dioxygenase (IDO) is of outstanding im-
portance in this process as it may take part in the immunoregu-
lation through Trp depletion and the production of 
kynurenines. Alterations in the balance of neurotoxic and neu-
roprotective kynurenines have been revealed in all phases of 
MS, which is supposed to contribute to the pathomechanism 
and progression of the disease [10]. In recent years, several 
compounds related to the KP have been developed with the 
aim to treat MS: synthetic tryptophan analogs, endogenous 
tryptophan metabolites, structural analogs, IDO inhibitors and 
kynurenine-3-monooxygenase inhibitors have been investigat-
ed [11]. Among these, laquinimod is the most promising drug. 
This review aims to give an overview of experimental findings 
on the role of the KP in the pathomechanism of MS and also 
of clinical trials evaluating the mode of action, safety, tolera-
bility and efficacy of laquinimod.  
THE KYNURENINE PATHWAY 
Trp is the precursor of several biologically active com-
pounds such as serotonin, melatonin, nicotinamide adenine 
dinucleotide (NAD) and approximately 1% takes part in pro-
tein biosynthesis. However, more than 95% of the Trp is 
metabolized through the KP (Fig. 1) [12]. The first and piv-
otal product of Trp degradation through the KP is L-
kynurenine (L-KYN), this rate-limiting step can be catalyzed by 
the enzymes tryptophan-2,3-dioxygenase (TDO) or IDO. TDO 
and IDO show differences in organ distribution and inducing 
factors as well. TDO is located almost exclusively in the liver, 
while IDO is present in most of the other tissues including 
the different cells of the CNS. L-KYN can be metabolized 
into different products of the KP, depending on the enzymat-
ic machinery present in the different cell types. The main 
branch of the KP is a cascade of enzymatic steps leading to 
the production of NAD, this branch gives rise to several neu-
rotoxic kynurenines as well. In this arm, L-KYN is trans-
formed by kynurenine-3-monooxygenase (KMO) into 3-
hydroxy-kynurenine (3HK), which consequently gives rise to 3-
hydroxy-anthranilic acid and quinolinic acid (QUIN). Anoth-
er possible transformation of L-KYN is the generation of 
kynurenic acid (KYNA) via the action of kynurenine-
aminotransferases (KATs). At present, four different KAT 
subtypes have been described, each of them possessing dif-
ferent biochemical properties [13]. Another side-arm of the 
KP is the synthesis of anthranilic acid by kynureninase, 
which is further transformed into 3-hydroxy-anthranilic acid. 
The enzymatic machinery of the KP is differently distributed 
between the cells of the CNS, e.g. astrocytes produce mainly 
KYNA because they lack KMO, while microglial cells syn-
thesize mainly the neurotoxic kynurenines [14, 15]. 
Peripheral Kynurenine Metabolism 
Under physiological conditions, the enzymatic machinery 
of the KP has a much higher activity at the periphery than in 
the CNS, and the hepatic KP is responsible for the metabo-
lism of more than 90% of Trp [16, 17]. Physiological con-
centrations of kynurenines have been measured in human 
plasma, but and hepatic concentrations have been also re-
ported measured directly form rat liver homogenates. The 
physiological concentrations of different kynurenines in the 
rat liver are 2.86±0.86 for 3HK, 0.10±0.01 for 3-hydroxy-
anthranilic acid, 0.07±0.02 for KYNA and 0.16±0.06 for 
anthranilic acid [16]. The effect of intraperitoneal admin-
istration of different kynurenines on hepatic KP has been 
investigated, and the results demonstrated that the activity of 
TDO is elevated by KYNA and by 3-hydroxy-anthranilic 
acid, but not by 3HK. Trp in a dose of 50mg/kg was also 
able to temporary increase TDO activity and the serum levels 
of kynurenines. Interestingly, the kyureninase inhibitors ben-
serazide and carbidopa were both able to enhance TDO ac-
tivity and reduce KAT activity in rat liver in this study [16]. 
However, previous in vitro investigations yielded confusing 
results, as they reported an inhibition of TDO by benserazide 
[18]. 
Neuroactive and Immunoregulatory Functions of 
Kynurenines 
The neurotoxic effect of QUIN is mainly due to its ca-
pacity to act as a potent agonist of N-methyl-D-aspartate 
(NMDA) receptors thereby inducing glutamatergic excitotox-
icity but it may also cause lipid peroxidation and oxidative 
stress [19, 20]. The other important neuroactive metabolite 
of the KP, KYNA has been suggested to have neuroprotec-
tive properties because it is able to counteract glutamatergic 
excitotoxicity through the antagonism of ionotropic gluta-
mate receptors [21]. KYNA acts as a competitive antagonist on 
NMDA receptors, in lower concentrations it binds to the 
strychnine-insensitive glycine binding site while at higher 
concentrations it is able to block the glutamate-binding site 
as well [22, 23]. On another ionotropic glutamate receptor, 
the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors KYNA exerts a concentration-dependent 
dual effect: in lower, nanomolar concentrations it is able to 
facilitate them, while in a higher concentration range it acts 
as an inhibitor [24, 25]. Another targets of KYNA are the 
presynaptic α7 nicotinic acetylcholine receptors, where it 
evokes inhibition, thereby reducing presynaptic glutamate 
release [26, 27].  
The possible immunoregulatory function of the KP is 
mainly related to the activation of IDO. IDO can be induced 
by proinflammatory cytokines such as interferon-γ, interleu-
kin-1 or tumor necrosis factor-α. IDO activation results in 
the elevated synthesis of kynurenines and Trp depletion. Trp 
depletion inhibits the proliferation of reactive lymphocytes 
[7]. Moreover, QUIN and 3-hydroxyanthranilic acid also 
directly lead to the selective apoptosis of TH1 lymphocytes 
[28]. IDO activation leads to the preferential inhibition of 
TH1 cells, but Trp depletion and the elevated level of 
kynurenines also increase the amount of regulatory T cells, 
which also inhibit TH2 cells. These effects are considered to 
contribute to the immunoregulation as a negative feedback 
[7, 29, 30].  
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THE ROLE OF KYNURENINES IN THE 
PATHOMECHANISM OF MS 
Experimental autoimmune encephalitis (EAE) is the most 
widely used animal model for MS because it is histologically 
similar to human MS [31, 32]. The importance of the im-
mune modulating effect of IDO in EAE has been confirmed 
by the fact that inhibition of the IDO led to a significantly 
decrease of the neuroinflammatory process and a decrease of 
the exacerbation [33]. Increased levels of the neurotoxic 3-
HK and QUIN have been measured in the spinal cords of 
EAE rats [34, 35]. QUIN in pathological concentrations re-
sults in neuronal, astroglial, and oligodendroglial cell death 
[36-38]. The clinical evidence on the implication of KP in 
MS was confirmed by the finding that Trp levels are lower in 
the serum and cerebrospinal fluid (CSF) of MS patients [39-
41]. On the other hand, the neurotoxic L-KYN was found to 
be elevated in IFN-β treated MS patients compared to un-
treated RRMS patients [42]. Levels of pro-inflammatory 
cytokines such as IFN-γ and TNF-α rise in MS patients, con-
sequently resulting in the activation of IDO [43]. IFN-β has 
been proved to be able to activate IDO in human macro-
phage cultures [44]. Importantly, levels of KAT enzymes in 
the red blood cells and plasma KYNA concentrations have 
been measured to be significantly elevated of MS patients 
compared to controls [45]. KYNA levels have been de-
scribed to be elevated also in the CSF of MS patients [46]. 
On the contrary, in postmortem MS brain sections reduced 
levels of KAT have been detected [47]. Interestingly, during 
remission, reduced KYNA serum levels while in acute re-
lapses elevated concentrations were measured in the CSF of 
MS patients [48, 49]. The explanation of these results might 
be the possible preventing role of KYNA in the acute phase 
while in the progressive phase the reduced KYNA levels 
reflect a metabolic shift in the KP towards neurotoxicity.  
THERAPEUTIC POSSIBILITIES RELATED TO THE 
KP 
The KP produces both and NMDA antagonist and an 
NMDA agonist compound, e.g. KYNA and QUIN, respec-
tively. An NMDA receptor antagonist has been described to 
be able to prevent blood-brain barrier breakdown in EAE 
[50]. KYNA and its pharmacological derivatives might 
therefore be a possible candidate for future drug develop-
ment. Notably, KYNA itself cannot cross the blood-brain 
barrier, this is possible only by synthetic KYNA analogs [51, 
52]. Several synthetic KYNA analogs have been synthesized 
in recent years, which proved to have better pharmacological 
properties than KYNA [53, 54]. Another alternative thera-
peutic intervention may be to achieve a shift in the KP to-
wards the formation of KYNA to reduce the level of neuro-
toxic compounds. Specific inhibitors of KMO, kynureninase 
and 3-hydroxi-anthranilic acid dioxygenase have been de-
veloped [55-57]. The systematic use of KMO inhibitors 
leads to decrease of 3HK and QUIN in parallel with the ele-
vation of the level of KYNA [34]. IDO-1 inhibitors result in 
significantly decreased QUIN concentration and prevention 
of oligodendrocyte apoptosis [58].  
Several Trp metabolites have been shown to have benefi-
cial effects in experimental models of MS. A synthetic Trp 
metabolite (N-[3,4-dimethoxycinnamoyl]-anthranilic acid 
(3,4-DAA), also known as Tranilas) resulted in decreased 
proliferation of myelin-specific T cells and inhibition of the 
proinflammatory cytokines produced by TH1 cells. The 
same analog, Tranilas in EAE animals significantly de-
creased to number and severity of relapses, and also the 
amount of inflammatory nodes in the brains and spinal cords 
of the treated animals. These data indicate the immunosup-
pressive effect of this molecule [59].  
Type-4 metabotropic glutamate receptor (mGlu4) knock-
out mice treated with the endogenous Trp metabolite cin-
nabarinic acid, which is the partial agonist of the mGluR4, 
the immune response was shifted toward T reg cell produc-
tion [60].  
The above mentioned therapeutic possibilities related to 
the KP are only in very preliminary phase of investigations. 
However, another molecule, laquinimod has already been 
widely investigated and is a potential immunomodulatory 
 
Fig. (1). The simplified scheme of the kynurenine pathway. 
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oral drug for the management of RRMS. Laquinimod is a 
quinoline carboxamide, which shows structural similarities with 
the KP metabolites 3-HAA, 3-HKA and KYNA, and it is also 
able to cross the blood-brain barrier (Fig. 2) [61-63]. Inter-
estingly, laquinimod is currently being investigated in Hun-
tington’ disease (NCT02215616), where also significant al-
terations of the KP have been described [64, 65]. A synthetic 
KYNA analog proved to have beneficial effects in an animal 
models of Huntington’s disease, which suggests that KYNA 
analogs and possibly laquinimod may be a future candidate 
for drug development in this disease [66].  
 
 
Fig. (2). Structural similarity of laquinimod and kynurenic acid. 
LAQUINIMOD 
Laquinimod was first synthetized by Jonsson et al. as a 
structural variant of roquinimex (Linomide®) [67]. Roquin-
imex showed promising results in phase II and III clinical 
trials in the treatment of MS, however phase III trials were 
stopped due to severe adverse events that included pericardi-
tis, myocardial infarction and serositis [68, 69]. Modifica-
tions were made to the quinolone ring and elongation of the 
amidic methyl group of roquinimex was carried out to 
achieve the chemical structure of N-ethyl-N-phenyl-5-
chloro-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-quinoline-
carboxamide (laquinimod) [67]. These alterations led to a 
significant reduction in severity of side effects and also to a 
marked increase in the efficacy of the drug. 
Pharmacokinetics 
Laquinimod is a small molecule with a molar mass of 
356,803g/mol [67]. 98% of laquinimod is bound to proteins 
in the plasma [70]. Since it is a small compound, it is able to 
diffuse freely across the blood-brain barrier (BBB) [71]. Its 
estimated concentration in the CNS is 13 % of the blood 
concentration [72]. For the time being, there are no known 
receptors for active transport of laquinimod. After admin-
istration, the plasma concentration reaches maximum level 
within an hour [73]. It is metabolized in microsomes of liver 
cells, mainly by CYP450 3A4 isoenzyme of the CYP 450 
(cytochrome P450) enzyme family [62]. 10 % of the drug is 
excreted without metabolism [74]. The half-life of laquini-
mod in humans is approximately 80 hours and it does not 
seem to accumulate in the body after prolonged administra-
tion. 
Modes of Action 
The exact mode of action of laquinimod has yet to be 
discovered, however several studies investigated its proper-
ties and proposed immunomodulatory and neuroprotective 
rather than immunosuppressive effects.  
Among other quinoline-3-carboxamide compounds, 
laquinimod binds to S100A9 in EAE mice [75]. This protein 
is found on the surface of different monocyte populations 
and is involved in signaling pathways that lead to secretion 
of pro-inflammatory molecules. Binding of this surface pro-
tein caused inhibition of interaction between S100A9 and 
two other receptors, toll-like receptor 4 (TLR-4) and receptor 
of advanced glycation end products (RAGE), therefore hin-
dering release of inflammatory cytokines (TNFα and IL-1). 
 Adhesion and migration of leukocytes in mice were in-
hibited by laquinimod by decreasing levels of matrix metal-
loproteinase 9 (MMP9) and very late antigen-4 (VLA-4) [76, 
77].  
Brück et al. studied the effects of laquinimod in rats and 
found decreased migration of T cells into the CNS, and a 
shift towards production of anti-inflammatory cytokines 
(TGFβ and IL-4) instead of pro-inflammatory molecules 
(TNFα and IL-12) [71]. These effects were found to be dose 
dependent.  
Another study investigated the effects of laquinimod on 
microglia [78]. Decreased density of microglia in the spinal 
cord of laquinimod treated EAE mice was found, which cor-
responded with reduced axonal damage. Furthermore, de-
creased secretion of both pro- and anti-inflammatory cyto-
kines was observed. Reduced production of TNFα was elic-
ited by stimulation of TLR 2 and 4.  
In laquinimod treated patients, decreased secretion of 
chemokines by mature dendritic cells was found after lipo-
polysaccharide stimulation [79]. Also, the number of Cd1c+ 
and plasmacytoid CD303+ dendritic cells was reduced 
among peripheral blood mononuclear cells. 
Gurevich at el. found in a high-throughput in vitro study 
that laquinimod reduced expression of MHC class II genes 
and, therefore hindered antigen presentation [80]. Also, al-
tered expression of genes involved in the NFκB pathway and 
T cell activation of B cells was found.  
It was reported that in vivo laquinimod treatment of mice 
resulted in reduction in CD4+ dendritic cells, which regulate 
differentiation of T-cells [81]. Consequently, reduced fre-
quencies of Th1 and Th17 cells along with an increase in 
regulatory T-cells were found. Also, augmented develop-
ment of type II monocytes and dendritic cells, which cause a 
shift towards anti-inflammatory cytokine production, was 
observed in the study. 
Laquinimod was shown to inhibit T cell secretion of 
INFγ, IL-17, granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and TNFα [79, 81]. In contrast, increased 
production of IL-4 by CD4+ T cells was observed, again 
pointing to a shift towards Th2 mediated immune response.  
An in vitro study found an increase after laquinimod 
treatment in CD86+ CD25+ and IL10+ CD25+ subpopula-
tions of B cells, which are involved in immunoregulatory 
functions [82]. Furthermore, these cells reduced T cell pro-
liferation and also the percentage of INFγ+ T cells, thus im-
plying beneficial effects in MS.  
Zilkha-Falb and colleagues examined gene expression al-
terations in patient participating in the ALLEGRO study, one 
and six months after initiation of treatment with laquinimod 
(0,6 mg/day) [83]. They observed significantly decreased 
TGFβ and NFκB signaling, furthermore reduced expression 
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of molecules involved in leukocyte activation, adhesion and 
transmigration (P-selectin, integrin family members: 
ITGB1/3/5/6/8 and ITGA8, metalloproteinase family mem-
bers: MMP16/24/26/28 and ADAM12/18/22, inflammatory 
chemokines: CCL19 and CXCR1/2). 
The proposed neuroprotective effect of laquinimod might 
be exerted by increasing the level of brain derived neu-
rotrophic factor (BDNF), which is produced not only by neu-
rons but also monocytes, B and T cells [84]. BDNF is essen-
tial to the development of the CNS via regulating synaptic 
plasticity, neuronal and axonal growth [85]. A study found in 
situ overexpression of BDNF in the striatum, lateral septal 
nucleus, nucleus accumbens and cortex of EAE mice after 
laquinimod treatment [86]. Also, increased frequency of 
immunosuppressive Foxp3+ Treg cells among inflammatory 
cells was observed. These findings were associated with re-
duced astrogliosis, axonal and myelin damage.  
Thöne et al. studied blood samples of 203 patients with 
MS treated with 0,6 mg/day dosage of laquinimod and found 
a significant increase in serum levels of BDNF in 76 % of 
patients compared to baseline and placebo-treated partici-
pants [87]. The same study group examined EAE mice after 
laquinimod treatment and found significantly reduced num-
bers of spleen-derived CD11b+ monocytes. 
Another study showed reduced inducible nitric oxide syn-
thase (iNOS) activation and therefore decreased levels of NO 
in the spinal cord of EAE mice [77]. NO is well known to 
have neurodegenerative effects by causing oxidative stress. 
Reducing the levels of this potent toxic agent might be another 
possible neuroprotective mechanism of laquinimod.  
Synaptic alterations due to laquinimod treatment were al-
so hypothesized. It was shown that slowed progression of 
EAE occurred after glutamatergic excitotoxicity decreased 
and GABAergic transmission was augmented by laquinimod 
treatment [88].  
In summary, based on the findings mentioned above, we 
conclude that laquinimod exerts its beneficial effects directly 
in the CNS and via modulating the immune system peripher-
ally. It has a widespread immunomodulatory effect. 
Laquinimod reduces activation and modulates the function of 
APCs (dendritic cells, macrophages, microglia in the CNS 
and even B-cells) thus hindering proliferation of T and B 
cells, which have a deleterious role in the pathogeneses of 
MS. In addition, a Th1/Th17 to Th2 shift has been put for-
ward. Consequently, reduction in the production of pro-
inflammatory cytokines and increase in anti-inflammatory 
molecules were observed. Migration of leukocytes into the 
CNS is also reduced by laquinimod. Furthermore, neuropro-
tective effects of laquinimod have been proposed. Elevated 
level of BDNF after laquinimod treatment, decreased activity 
of iNOS and reduced glutamatergic excitotoxicity has been 
reported. All these effects lead to reduced demyelination, 
axononeural damage and cell death (Fig. 1). 
CLINICAL STUDIES 
Phase I Trials 
So far 8 phase I studies have been conducted to investi-
gate the safety, tolerability and pharmacokinetic properties 
of laquinimod in healthy volunteers and MS patients [62, 
89]. Doses between 0.1-2.4 mg/day were studied. Laquini-
mod was found to be well tolerated.  
Phase II Trials 
Polman at el. conducted a multicenter, double-blind, ran-
domized, placebo controlled and three armed trial [63]. 209 
RRMS patients (Expanded Disability Status Scale [EDSS] 
no greater than 5.5 and active disease according to MRI cri-
teria) were divided into three groups receiving 0.3 mg/day; 
0.1 mg/day of laquinimod or placebo for 24 weeks. Primary 
outcome measure was the mean cumulative number of active 
lesions on brain MRIs. A significant reduction (44%; 
p=0.0498) of the mean cumulative number of active lesions 
was observed in the 0.3 mg/day laquinimod group compared 
to the placebo group. A more pronounced effect was found 
in those patients who had at least one active lesion at base-
line MRI (54% reduction; p=0.005). No significant differ-
ence was observed in the primary end point in the 0.1 
mg/day laquinimod group. Although the study did not aim to 
assess clinical end points, EDSS and MSFC (Multiple Scle-
rosis Functional Composite) were measured, but no signifi-
cant differences were found in these scores between groups 
over the 24 weeks. Laquinimod was found to be well tolerat-
ed during the study. 
The second phase II study was a multicenter, double-
blind, randomized and placebo controlled 36 weeks long trial 
[90]. 306 RRMS patients (EDSS between 1 and 5, with at 
least one relapse in the previous year and at least one gado-
linium enhancing lesion on brain MRI) were randomly as-
signed to 0.3 mg/day; 0.6 mg/day of laquinimod or placebo. 
The primary objective was to assess changes in the number 
of gadolinium enhancing (Gd+) lesions at 24, 28, 32 and 36 
weeks. The authors reported 40.4 % (p=0.0048) reduction in 
the cumulative number of Gd+ lesions in the 0,6 mg/day 
laquinimod group. Furthermore, 44 % (p=0.0013) decrease 
in the cumulative number of new T2 lesions and 51 % 
(p=0.0064) reduction in the number of new T1-hypointense 
lesions were found in the same group compared to the place-
bo arm. Strikingly, the 0.3 mg/day laquinimod group showed 
no significant difference compared to the placebo group, 
contradicting the findings of the previous phase II study. It 
was hypothesized, that the triple dose gadolinium used in the 
study by Polman et al. resulted in increased sensitivity, and 
also a possible slower onset of low-dose laquinimod com-
pared to the higher dose could explain this observation. One 
case of Budd-Chiari syndrome occurred in a patient who was 
heterozygous for factor V Leiden mutation. Herpes simplex 
and herpes zoster infections were more common in the 0.3 
mg/day laquinimod group. Mild arthralgia and transiently 
elevated liver enzymes were the most common adverse 
events. 
A double-blind, 36 week-long extension of the study was 
conducted enrolling 257 out of 306 participants [91]. Pa-
tients previously on placebo were given either 0.3 mg/day or 
0.6 mg/day laquinimod. Main outcome measures were the 
number of new Gd+ lesions and the number of new hy-
pointense T1 lesions. Among the participants who were 
switched from placebo, a 52 % (p=0.0006) reduction in the 
mean number of Gd+ lesions was found. The effect on new 
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hypointense T1-lesions was statistically nonsignificant. Pa-
tients who were initially treated with laquinimod continued 
to have a sustained effect. Beneficial effect on clinical scores 
(EDSS and MSFC) were also nonsignificant. No deaths or 
serious adverse events were reported in the study. 
An open-label extension of the core and double-blind 
study conducted by Comi et al. was carried out, in which all 
209 participants received 0.6 mg/day of laquinimod, regard-
less of what their therapy in the previous trials was [91]. 155 
patients reached 24 months of the study. The confirmed dis-
ability progression on EDSS decreased from 14.8 % to 10.5 
% during the initial 18 months. 61 % of patients remained 
free of Gd+ lesions on 42 months. The most common ad-
verse events were nasopharyngitis, back pain and headache. 
Phase III Trials 
The ALLEGRO (Assessment of Oral Laquinimod in Pre-
venting Multiple Sclerosis) study was a randomized, double-
blind, placebo-controlled, phase III clinical trial involving 24 
countries [92]. 1106 patients with RRMS (EDSS no greater 
than 5.5 and a disease duration of at least 6 months) were 
enrolled. They received 0.6 mg/day laquinimod or placebo 
for 24 months. The primary end point was the number of 
confirmed relapses. Secondary clinical end points were disa-
bility progression on EDSS and MSFC scores sustained for 
at least 3 months. Secondary imaging end points were the 
cumulative number of Gd+ lesions and the cumulative num-
ber of new or enlarged lesions on T2-weighted images at 12 
and 24 months. The annualized relapse rate showed a statis-
tically significant, albeit modest reduction (0.30±0.02 vs. 
0.39±0.03, p=0.002) in the laquinimod group. The secondary 
disability progression end point was significantly decreased 
in the laquinimod group (11.1% vs. 15.7%, p=0.01). Howev-
er, little overall change was observed in the MSFC scores at 
24 months. Laquinimod showed beneficial effects on both 
secondary MRI end points. The mean cumulative number of 
Gd+ lesions and new or enlarged lesions on T2-weighted 
images were reduced (p<0.001 in both cases). 112 serious 
adverse events were reported in 61 patients in the laquinimod 
group. Appendicitis occurred more often compared to the 
placebo group (5 vs. 1 respectively). 8 cases of neoplasms 
occurred in the laquinimod group compared to 6 in the pla-
cebo arm. The most frequent adverse events included ab-
dominal pain, back pain, cough and elevated levels of ala-
nine aminotransferase. This finding was reversible in all cas-
es without discontinuation of laquinimod or after 2 months 
of discontinuation. No cases of liver failure occurred. An 
open-label extension is currently ongoing with 844 out of the 
864 patients who finished 24 months with the study drug. 
The BRAVO (Benefit-Risk Assessment of Avonex and 
Laquinimod) study was the second phase III clinical trial, 
with the aim to further assess the safety, tolerability and effi-
cacy of laquinimod and to descriptively compare its effect 
with interferon-beta 1a (INFβ-1a, Avonex®) [93]. 18 coun-
tries were involved in the randomized, placebo-controlled 
24-month trial. 1331 RRMS patients (18-55 years of age; 
EDSS no greater than 5.5; at least one relapse in the last 12 
months, two relapses in the past 24 months or one relapse in 
the past 12-24 months and one Gd+ MRI lesion in the previ-
ous 12 months) were enrolled, and received 0.6 mg/day 
laquinimod, matching placebo or INFβ-1a intramuscular 
injection 30 µg once a week. 1090 participants completed the 
trial. The primary endpoint was the annualized relapse rate 
over the 24 months of the trial. Secondary endpoints were 
the percent change in normalized brain volume, and disabil-
ity progression measured by EDSS and MSFC scores. Ex-
ploratory MRI endpoints included the cumulative number of 
Gd+ lesions and cumulative number of new or enlarging T2 
lesions at 12 and 24 months. Laquinimod showed a decrease 
in annualized relapse rate, which was statistically nonsignifi-
cant compared to placebo (0.28±0.03 vs. 0.34±0.03, 
p=0.075). However, after adjustment for imbalance between 
groups in baseline MRI disease activity, a statistically signif-
icant 21 % (p = 0.0264) reduction in annualized relapse rate 
was demonstrated. Percent brain volume change was signifi-
cantly reduced in the laquinimod group (treatment effect vs. 
placebo 0,28 %, p<0.001). In contrast, INFβ-1a treatment did 
not show beneficial effects on brain volume compared to 
placebo (treatment effect -0.11 %, P=0.14). The reduction in 
disability progression in the laquinimod group was 40.6 % 
(p=0.042) at six months. INFβ-1a showed a nonsignificant 
reduction in disability worsening (28.3 %, P=0.14) at six 
months compared to placebo. A nonsignificant reduction in 
the laquinimod group was observed regarding exploratory 
MRI endpoints, whereas INFβ-1a treatment showed signifi-
cant reductions. Descriptive comparison of laquinimod and 
INFβ-1a therapy did not show significant differences in an-
nualized relapse rate, EDSS and MSFC scores, however 
laquinimod had a more pronounced beneficial effect on brain 
volume loss compared to INFβ-1a. One death occurred in the 
laquinimod group due to sepsis after early termination. The 
most common adverse events with laquinimod treatment 
were headache, increased alanine transaminase levels, ab-
dominal pain and nausea. No cases of liver failure were re-
ported.  
The clinical trials with laquinimod (Table 1) showed 
modest effects on focal inflammatory activity of MS, but 
demonstrated significant beneficial effects on reduction of 
brain atrophy and disability progression. Laquinimod was 
found to be safe and well tolerated. The most common ad-
verse event was increase in liver enzymes, however no cases 
of liver failure were observed in any of the clinical trials.  
Ongoing Clinical Trials 
The third phase III clinical trial assessing the safety, tol-
erability and efficacy of a higher dose of laquinimod is the 
CONCERTO (The Efficacy and Safety and Tolerability 
of Laquinimod in Subjects With Relapsing Remitting Multi-
ple Sclerosis) trial, which is currently in progress but not 
recruiting participants. It is a multinational, multicenter, ran-
domized, double-blind, parallel-group, placebo-controlled 
study evaluating two different doses of laquinimod (0.6 
mg/day vs. 1.2 mg/day) in patients with RRMS.  
Previous clinical trials and animal studies suggest that 
laquinimod might exert neuroprotective effects. Based on 
these findings, two ongoing trials investigate the effect of 
laquinimod in diseases where neurodegeneration plays a 
prominent role in disease pathomechanism [88]. 
The ARPEGGIO (A Randomized Placebo-Controlled Tri-
al Evaluating Laquinimod in Primary Progressive Multiple
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Table 1. Summary of clinical trials with laquinimod. 
Clinical Study 
No. of 
Patients 
Groups Results 
Phase IIa  
(Polman et al. 2005) 
209 
LAQ 0.3 mg/day; LAQ 
0.1 mg/day; placebo 
Reduction of mean cumulative no. of active lesions (44 %; p= 0.0498) in LAQ 
0.6 mg/day group 
No significant difference in LAQ 0.1 mg/day group vs. placebo group 
No significant differences in EDSS and MSFC 
Phase IIb (Comi et al. 2008) 306 
LAQ 0.6 mg/day; LAQ 
0.3 mg/day; placebo 
Reduction in the cumulative no. of Gd+ lesions (40.4 %; p=0.0048) in LAQ 0.6 
mg/day group 
Decrease in the cumulative no. of new T2 lesions (44 %; p=0.0013) in LAQ 0.6 
mg/day group 
Reduction in the no. of new T1-hypointense lesions (51 %; p=0.0064) in LAQ 
0.6 mg/day group 
LAQ 0.3 mg/day group showed no significant difference vs. placebo group 
Phase IIb double-blind exten-
sion (Comi et al. 2010) 
257 
LAQ 0.6 mg/day; LAQ 
0.3 mg/day 
Reduction in the mean no. of Gd+ lesions in patients switched from placebo to 
LAQ (52 %; p=0.0006) 
Sustained effect on patients continued on LAQ 
Nonsignificant effect on EDSS and MSFC 
Phase IIb open-label exten-
sion (Comi et al. 2010) 
209 LAQ 0.6 mg/day 
Confirmed disability progression on EDSS decreased from 14.8 % to 10.5 % 
61 % of patients remained free of Gd+ lesions 
Phase III ALLEGRO  
(Comi et al. 2012) 
1106 
LAQ 0.6 mg/day;  
placebo 
Modest reduction in ARR (0.30±0.02 in LAQ vs. 0.39±0.03, p=0.002 in placebo 
group) 
Disability progression on EDSS and MSFC scores decreased in LAQ group 
(11.1 % vs. 15.7 %, p=0.01) 
Reduced mean cumulative no. of Gd+ lesions in LAQ group (p<0.001) 
Reduced new or enlarged lesions on T2-weighted images in LAQ group 
(p<0.001) 
Phase III BRAVO  
(Vollmer et al. 2014) 
1331 
LAQ 0.6 mg/day; 
INFβ-1a 30 µg/week; 
placebo 
Nonsignificant decrease in ARR in LAQ vs. placebo group (0.28±0.03 vs. 
0.34±0.03, p=0.075) 
After adjusted analysis statistically significant 21 % (p = 0.0264) reduction in 
ARR in LAQ vs. placebo group 
Percent brain volume change reduced in LAQ vs. placebo group (treatment 
effect vs. placebo 0,28 %, p<0.001) 
40.6 % reduction in disability progression in LAQ vs. placebo group (p=0.042) 
Descriptive comparison of LAQ and INFβ-1a did not show significant differ-
ences in ARR, EDSS and MSFC scores 
ALLEGRO: Assessment of Oral Laquinimod in Preventing Multiple Sclerosis, ARR: annualized relapse rate, BRAVO: Benefit-Risk Assessment of Avonex and Laquinimod, EDSS: 
Expanded Disability Status Scale, Gd+: gadolinium enhancing, INFβ-1a: interferon beta-1a, LAQ: laquinimod, MSFC: Multiple Sclerosis Functional Composite. 
Sclerosis, Gauging Gradations in MRI and Clini-
cal Outcomes) trial is a phase II trial aimed at assessing effi-
cacy, safety and tolerability of two oral doses of laquinimod 
(0.6 mg/day or 1.5mg/day) as compared to placebo in prima-
ry progressive MS patients. 
The third ongoing clinical trial with laquinimod is the 
phase II LEGATO-HD (Laquinimod Efficacy and Safety in a 
Global Trial Of Huntington’s Disease) trial, which evaluates 
the efficacy and safety of three oral doses of laquinimod 
(0.5, 1.0 and 1.5 mg/day) in patients with Huntington’s dis-
ease. 
Despite the positive results of clinical trials, the Commit-
tee for Medicinal Products for Human Use (CHMP) rejected 
approval for laquinimod in 2014 [89]. According to the 
CHMP, higher occurrence of malignancy was observed after 
long-term exposure to laquinimod in animal studies. Despite 
that no treatment related cancer was observed in clinical tri-
als, the CHMP stated that long-term cancer risk after 
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laquinimod treatment could not be ruled out. Also, the 
CHMP noted that again, based on animal studies, there is a 
possible teratogenic effect of laquinimod. Since there was 
only a modest effect of laquinimod in clinical trials, the 
CHMP concluded, that the potential risk of long-term 
laquinimod treatment currently outweighs its beneficial ef-
fect on reducing disability progression in RRMS patients and 
rejected its approval in the European Community. 
Another setback for laquinimod is that in the CONCER-
TO and ARPEGGIO trials 8 cardiovascular (possibly is-
chemic) events were reported with higher doses of laquini-
mod [90, 91]. Seven adverse events were observed in the 
CONCERTO trial with 1.2 mg/day laquinimod and one 
event in the ARPEGGIO trial in the 1.5 mg/day laquinimod 
group. Consequently, the higher dose arm of these two ongo-
ing trials (CONCERTO, ARPEGGIO) and the highest dose 
of the LEGATO-HD trial were discontinued in early 2016 
[92]. No cardiovascular adverse events were reported in the 
lower dose arm of the studies and all three trials continue 
with the 0.6 mg/day laquinimod arm and 1 mg/day arm in 
the LEGATO-HD study.  
CONCLUSION 
Based on the clinical and experimental studies, laquini-
mod might be a suitable medication for combination therapy 
in MS. Since it is an oral, once-a-day medication, patient 
compliance, adherence and satisfaction should improve 
compared to the parenteral medications currently in the first 
line armamentarium of MS treatment. Influencing the KP 
might offer a valuable therapeutic option in MS and other 
autoimmune diseases. KYNA analogs, KP enzyme inhibitors 
or structural analogs of kynurenines might offer promising 
candidates for future drug development.  
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